Serial Number
97503907
Owner
Lario Therapeutics LtdAttorney
Deborah J. PeckhamFiling Date
Jul 14, 2022
LARIO THERAPEUTICS Trademark
Serial Number: 97503907 • Registration: 7637354
Trademark Classes
Class 5 - Pharmaceuticals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Class 42 - Computer & Scientific
Scientific and technological services; industrial analysis and research services
Class 44 - Medical Services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Owner Contact Info
Legal Representation
Correspondence Address
Deborah J Peckham Barclay Damon LLP
160 Federal Street, Suite 1001
BOSTON, MA 02110
United States
Trademark Details
Filing Date
July 14, 2022
Registration Date
January 7, 2025
Published for Opposition
March 5, 2024
Goods & Services
Pharmaceutical preparations for the treatment of neurological conditions; veterinary preparations for the treatment of neurological disorders; chemical preparations for medical and pharmaceutical purposes, namely, for the treatment of neurological disorders; pharmaceutical preparations for the treatment of neurological disorders; pharmaceutical preparations for the treatment of central nervous system disorders; pharmaceutical preparations for the treatment of neuro-degenerative diseases; pharmaceutical preparations for the treatment of Parkinson's disease
Medical consultation services featuring preparation of reports relating to medical and pharmaceutical services
Research, development, evaluation and design services in the fields of medical, biological, biotechnological, genetic, laboratory and pharmaceutical and veterinary preparations and medications; research, development and design of drugs and medicine, veterinary preparations, laboratory and medical laboratory research and development services; research, development, evaluation and design services in relation to neurological disorders; research, development, evaluation and design services in relation to central nervous system disorders; research, development, evaluation and design services in relation to neuro-degenerative diseases; research, development, evaluation and design services in relation to Parkinson's Disease; exploitation of scientific research and technology, namely, providing information relating to scientific and technological research in the fields of drugs, pharmaceuticals and medicines in the nature of reports; development of prognostic and diagnostic tools; consultancy and information services relating to all of the aforesaid
